- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- DE-117 Low Dose ophthalmic solution, DE-117 Low/Middle Dose ophthalmic solution, DE-117 Middle Dose ophthalmic solution, DE-117 Middle/High Dose ophthalmic solution, DE-117 High Dose ophthalmic solution, latanoprost ophthalmic solution 0.005%
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 14
- States / cities
- Chandler, Arizona • Artesia, California • Glendale, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Open-angle Glaucoma or Ocular Hypertension
- Interventions
- DE-117 ophthalmic solution, latanoprost ophthalmic solution, Placebo
- Drug · Other
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 7
- States / cities
- Newport Beach, California • Morrow, Georgia • Kansas City, Missouri + 4 more
- Conditions
- Primary Open-angle Glaucoma and Ocular Hypertension
- Interventions
- DE-117 Ophthalmic Solution QD, DE-117 Ophthalmic Solution BID
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Danbury, Connecticut • Brooksville, Florida + 10 more
- Conditions
- Glaucoma and Ocular Hypertension
- Interventions
- DE-117, 0.0015% tafluprost, DE-117 and 0.0015% tafluprost, Placebo
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 10
- States / cities
- Newport Beach, California • Deerfield Beach, Florida • Largo, Florida + 7 more
- Conditions
- Primary Open-angle Glaucoma and Ocular Hypertension
- Interventions
- DE-117 Ophthalmic Solution
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 32
- States / cities
- Chandler, Arizona • Glendale, California • Mission Hills, California + 28 more
- Conditions
- Glaucoma and Ocular Hypertension
- Interventions
- DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 12 Months and older
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Burbank, California + 40 more
- Conditions
- Glaucoma and Ocular Hypertension
- Interventions
- DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 12 Months and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 34
- States / cities
- Chandler, Arizona • Prescott, Arizona • Glendale, California + 29 more